Combination of Thrombolysis and Glycoprotein IIb/IIIa Inhibition in Chronic Peripheral Thrombosis: A Case Report
Journal Title: International Journal of Radiology and Radiation Oncology - Year 2017, Vol 3, Issue 1
Abstract
Currently, many interventionalists employ either tissue plasminogen activator (alteplase, Genentech, San Francisco, CA), or recombinant plasminogen activator (reteplase, Chiesi USA, Inc., Cary, NC), for peripheral thrombolysis. Further, combination therapy utilizing a thrombolytic agent and a glycoprotein IIb/IIIa receptor antagonist has been proposed as a way to overcome the limitations of thrombolytic therapy alone by reducing the duration of infusion, preventing rethrombosis, and improving the efficacy of thrombolysis. The following report discusses a patient with stenoses in the distal right posterior tibial artery. The patient underwent percutaneous transluminal angioplasty along with tissue plasminogen activator infusion therapy. Initially, the tissue plasminogen activator infusion reduced pain. However, an embolic occlusion to the distal right lateral plantar artery led to recurrence of pain. Due to failure of thrombolytic monotherapy using tissue plasminogen activator, a combined treatment of eptifibatide (Integrilin, Cor Therapeutics and Schering-Plough) and tissue plasminogen activator infused intra-arterially was initiated. In this report, the successful clinical use of combination therapy has been demonstrated after failed intra-arterial tissue plasminogen activator infusion monotherapy. The use of purely intra-pedal intra-arterial eptifibatide is novel and should be studied in randomized trials to establish efficacy. Furthermore, we have shown that failure of monotherapy to treat occlusions can be recovered through the use of combination therapy.
Authors and Affiliations
Syed Mubin I, Gallagher Ryan, Hussain Zeshan, Shaikh Azim, Cain Philip J, Morar Kamal, Guehl Allen, Erdelyi Ronald
Keywords
Related Articles
- EP ID EP541303
- DOI 10.17352/ijrro.000020
- Views 68
- Downloads 0
Direct and Bystander Effect on Cervix Cancer Cells (SiHa) Exposed to High Dose-Rate Gamma Radiation Sourced from Ir192 Used in Brachytherapy
Introduction: Brachytherapy is a preferred choice of radiotherapy in the treatment of sensitive tissues cancer like intestine and gonad. The treatment is expensive because of the frequent replacement of radionuclide sour...
Successful Treatment of a Bilateral Lower Palpebral MALT Lymphoma with Rapid Arc: Description of a New Technique
Primary MALT lymphoma of the eyelids is a rare disease; chronic infection by Chlamydophila psittaci has been identified as a possible causative agent, but other pathogens may be implicated such Hepatitis C virus and Heli...
MR Imaging of Pregnant Women with Abdominal Pain and Suspected Appendicitis: Diagnostic Accuracy and Outcomes
Acute appendicitis is the most common cause of acute surgical abdomen during pregnancy. Our study was conducted to review our experience and diagnostic accuracy with MRI during pregnancy and clinical outcomes over a two...
Sclerosing Angiomatoid Nodular Transformation of the Spleen (SANT): CT and MR Imaging Features of Five Cases with Pathological Correlation
Objective: To describe imaging features of sclerosing angiomatoid nodular transformation (SANT) with pathologic correlation. Methods: Imaging findings of five cases of SANT were retrospectively analyzed and compared with...
Combination of Thrombolysis and Glycoprotein IIb/IIIa Inhibition in Chronic Peripheral Thrombosis: A Case Report
Currently, many interventionalists employ either tissue plasminogen activator (alteplase, Genentech, San Francisco, CA), or recombinant plasminogen activator (reteplase, Chiesi USA, Inc., Cary, NC), for peripheral thromb...